TODAY: Treatment of Type 2 Diabetes in Children and Adolescents
No longer recruiting
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) sponsored this collaborative multi-center diabetes prevention and treatment program of research entitled the Studies to Treat or Prevent Type 2 Diabetes (STOPP-T2D). The treatment arm of the program is entitled Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY). This fifteen-center clinical trial compares three treatment arms on time to treatment failure based on glycemic control: metformin, metformin plus rosiglitazone, or meformin plus an intensive lifestyle intervention. At this time, over 700 youth (ages 10 to 17 years) with type 2 diabetes, and their families have been enrolled in the TODAY study nation-wide.
- Children between ages of 10 and 17
- Child recently (within past 2 years) diagnosed with type 2 diabetes mellitus (T2DM)
- At least one parent/caregiver willing to participate in program with child